Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences
BTIG Virtual Healthcare Conference2021
- Fireside chat
Tuesday, August 10at 1:00 PM ET
Wedbush PacGrow Healthcare Virtual Conference
- "Live-r Let Die – Updates in Liver Disease" panel discussion
Tuesday, August 10at 2:20 PM ET
A live webcast of the Wedbush PacGrow panel discussion will be available on the
Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.
Zokinvy® for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient progeroid laminopathies is the Company's first FDA approved product. A Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA).
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Investors and Media:
Email: [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences-301347526.html